Effects of PA-1 Transcriptional Regulation on Monocyte Function

Atherosclerosis Clinical Trial

Official title:

Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00512369
• Other study ID #: 060286
• Secondary ID: NIH
• Status: Terminated
• Phase: N/A
• First received: August 3, 2007
• Last updated: July 14, 2011
• Start date: March 2006
• Est. completion date: July 2011

Study information

• Verified date: July 2011
• Source: Vanderbilt University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Researching genetic differences in people with no prior medical conditions for better understanding of cardiac diseases through genetic research.

Description:

The discovery and subsequent application of small interfering RNA (siRNA) methods to achieve individual gene silencing in mammalian cells is a robust method that is well-described and validated in mammalian cell culture systems. We will apply this technique to achieve post-transcriptional "silencing" of PAI-1 in monocytes obtained from otherwise healthy volunteers, and study the subsequent loss of this gene's function on the migratory capacity of these cells in the proposed in vitro experimental system. This concept has not yet been demonstrated in the literature, and if validated, would be a novel and fundamental description of the role of PAI-1 in human monocyte biology as related to the development of atherosclerosis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 125
• Est. completion date: July 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Ages 18 -50

• No current or past medical problems

Exclusion Criteria:

• Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Atherosclerosis

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States,